Prevalence and Predictors of Adverse Drug Events from Favipiravir in Patients with Coronavirus Disease 2019
Article Sidebar
Main Article Content
Abstract
Objective: To investigate the prevalence and predictors of adverse drug events associated with favipiravir use in the treatment of patients with Coronavirus Disease 2019 (COVID-19). Methods: This retrospective study analyzed data from electronic databases and inpatient medical records at Buddhachinaraj Hospital, Phitsanulok, between April 1, 2021 and December 31, 2021. The study included patients aged 18 and older who were hospitalized with COVID-19 and treated with favipiravir. Prevalence and predictors of adverse drug events from favipiravir were analyzed using descriptive statistics and logistic regression. Results: A total of 2,231 COVID-19 patients treated with favipiravir were included in the study. The mean age was 46.96±17.24 years. COVID-19 was diagnosed via RT-PCR in 1,920 patients (86.1%), and 399 patients (17.9%) were admitted to intensive care units. Adverse drug events from favipiravir occurred in 171 patients (7.7%), with elevated liver enzymes being the most common (104 patients, 4.7%). Other adverse events included dizziness, rash, hyperuricemia, and diarrhea. Predictors of adverse events from favipiravir included concurrent use of steroids (adjusted OR = 1.58, 95% CI = 1.10-2.26, P = 0.013) and parenteral anticoagulants (adjusted OR = 1.98, 95% CI = 1.24-3.16, P = 0.004). Conclusion: Rate of adverse drug events from favipiravir in the treatment of COVID-19 patients were 7.7%. Common adverse drug events included elevated liver enzymes, dizziness, rash, hyperuricemia, and diarrhea. The predictive factors associated with adverse events include receiving steroids and parenteral anticoagulants in concurrent with favipiravir.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506.
World Health Organization. Global excess deaths associated with COVID-19, January 2020 - December 2021 [online]. 2022 [cited May1, 2023]. Available from: www.who.int/data#rep.
Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 2020; 76: 370-6.
Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002; 46: 977-81.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing) 2020; 6: 1192-8.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: A prospective, multicenter, open-label, randomized controlled clinical trial. Front Pharmacol 2021; 12: 683296.
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021; 103: 62-71.
McMahon JH, Lau JSY, Coldham A, Roney J, Hagenauer M, Price S, et al. Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. eClinicalMedicine 2022; 54: 101703.
Ozlusen B, Kozan S, Akcan RE, Kalender M, Yaprak D, Peltek IB, et al. Effectiveness of favipiravir in COVID-19: A live systematic review. Eur J Clin Microbiol Infect Dis. 2021; 40: 2575-83.
Ergur F, Yildiz M, Sener MU, Kavurgaci S, Ozturk A. Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study. Sao Paulo Med J. 2022; 140: 372-7.
Reddy PK, Patil S, Khobragade A, Balki A, Raj A, Kalikar M, et al. Evaluation of the safety and efficacy of favipiravir in adult indian patients with mild-to-moderate COVID-19 in a real-world setting. Int J Gen Med 2022; 15: 4551-63.
Department of Disease Control. Corona virus disease (COVID-19) [online]. 2022 [cited Jul 16, 2024]. Available from: ddc.moph.go.th/viralpneumo nia /index.php
Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, et al. Early treatment of favipiravir in COVID-19 patients without pneumonia: A multicentre, open-labelled, randomized control study. Emerg Microbes Infect 2022; 11: 2197-206.
Cochran WG. Sampling techniques. 3rd ed. New York: John Wiley & Sons; 1977.
World Health Organization. The use of the WHO-UMC system for standardised case causality assessment [online]. 2021 [cited May 1, 2023]. Available from: www.who.int/publications/m/item/ WHO -causality-assessment.
Siripongboonsitti T, Tawinprai K, Cheirsilpa K, Ungtrakul T, Krisorakun W, Chotipanich C, et al. The real-world clinical outcomes of favipiravir treatment with telemedicine monitoring in preventing disease progression in mild to moderate COVID-19 patients; A retrospective cohort study. Medicina (Kaunas). 2023; 59: 1098.
Ulugerger Avci G, Bektan Kanat B, Suzan V, Can G, Korkmazer B, Karaali R, et al. Clinical outcomes of geriatric patients with COVID-19: review of one-year data. Aging Clin Exp Res 2022; 34: 465-74.
Yilmaz H, Güner E, Altuntas M. Results of favipiravir combined treatment in intensive care patients with Covid-19. Bagcilar Med Bull. 2020; 6: 339-45.
Al-Muhsen S, Al-Numair NS, Saheb Sharif-Askari N, Basamh R, Alyounes B, Jabaan A, et al. Favipiravir effectiveness and safety in hospitalized moderate-severe COVID-19 patients: Observational prospective multicenter investigation in Saudi Arabia. Front Med (Lausanne). 2022; 9: 826247.
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2024; 78: e250-e349. doi: 10.1093/cid/ciac724 .2020.
Shah PL, Orton CM, Grinsztejn B, Donaldson GC, Crabtree Ramírez B, Tonkin J, et al. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. Lancet Respir Med 2023; 11: 415-24.
Kaur RJ, Charan J, Dutta S, Sharma P, Bhardwaj P, Sharma P, et al. Favipiravir use in COVID-19: Analysis of suspected adverse drug events reported in the WHO database. Infect Drug Resist 2020; 13: 4427-38.
Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, et al. Ebola virus infection: Review of the pharmacokinetic and pharmacody- namic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 2016; 55: 907-23.
Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021; 11: 11022.
Mishima E, Anzai N, Miyazaki M, Abe T. Uric acid elevation by favipiravir, an antiviral drug. Tohoku J Exp Med. 2020; 251: 87-90.
Hanai Y, Yoshizawa S, Matsuo K, Uekusa S, Miyazaki T, Nishimura K, et al. Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir. Diagn Microbiol Infect Dis. 2022; 102: 115640.
Nakaranurack C, Santimaleeworagun W, Suwanpi- molkul G, Weeraphon B, Charoenwaiyachet W, Torvorapanit P. Clinical experience and adverse drug events of favipiravir use in real-world data, Thailand. Thai J Pharm Sci 2023; 47: e5.
